Refine by
Biopsy Test Articles & Analysis
4 articles found
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta Innovates AICE-Concepts Program with a ...
NEW YORK - Spanish cancer research firm Universal Diagnostics is gearing up to commercialize a liquid biopsy test that applies methylation biomarkers to detect lung cancer, based on data presented at the International Association for the Study of Lung Cancer 2020 World Conference for Lung Cancer (WCLC) last month. The Seville-based firm also expects to release clinical data on its next ...
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the clinical validation study This partnership will ...
This case study is presented to highlight how medical calculators can be useful clinical decision making tools for celiac disease diagnosis. Throughout the discussion, links to medical calculators that healthcare providers can use are provided. Incorporating these resources into a clinician’s workflow can lead to better outcomes through more accurate diagnoses and better management for this ...